2023-510356-23-00
Not yet recruiting
Phase 1
Phase I open-label, multi-center study to evaluate the safety, tolerability, dosimetry, and preliminary activity of [177Lu]Lu-NNS309 in patients with pancreatic, lung, breast and colorectal cancers.
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Novartis Pharma AG
- Enrollment
- 76
- Locations
- 14
- Status
- Not yet recruiting
- Last Updated
- 10 months ago
Overview
Brief Summary
No summary available.
Investigators
Novartis Pharma Arzneimittel GmbH
Scientific
Novartis Pharma AG
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Not specified
Study Sites (14)
Loading locations...
Similar Trials
Recruiting
Phase 1
A Phase 1 Prospective, Open-label, First-in-human Study to Evaluate the Safety, Tolerability and Biodistribution of [177Lu]Lu-AKIR001 and its Anti-tumour Effect in Adult Patients with CD44v6 Expressing Solid Tumours2023-508126-95-00Karolinska University Hospital30
Recruiting
Phase 3
Ulcerative Colitis: Efficacy, Safety, and Pharmacokinetics of Upadacitinib in Pediatric Subjects with Moderately to Severely Active Ulcerative Colitis2022-501788-41-00Abbvie Deutschland GmbH & Co. KG40
Recruiting
Phase 1
BY002 IIT Study in R/R Acute LeukemiaNCT07270770The First Affiliated Hospital of Soochow University18
Completed
Phase 1
A randomized, open-label, single dose, cross-over study to evaluate the drug-drug interaction between Proscar 5 mg, film-coated tablets and Cialis 5 mg film-coated tablets when co-administered versus the administration of each product alone in healthy volunteers under fasting conditions. Study no. FIN-TAD-DDI-03-242024-510774-24-00Adamed Pharma S.A.30
Recruiting
Phase 2
A Phase II Study of PEG-rhGH Injection for Short Children Born Small for Gestational Age: Efficacy, Safety, and PharmacokineticsNCT07260500Changchun GeneScience Pharmaceutical Co., Ltd.72